# A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

> **NCT01104519** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Niaspan
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT01104519
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104519, "A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01104519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*